anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to gynecology, and can be used for the complex treatment of kraurosis and/or leukoplakia of the vulva. Treatment is carried out in two stages. At first stage of treatment, photodynamic therapy (PDT) is performed. To do this, intravenously injected photosensitizer at a rate of 0.7–1.2 mg/kg. Then, after 2–3 hours, fluorescent diagnostics is performed and irradiation time is calculated. As radiator, laser device with wavelength of 662 nm is used when using a fiber with a straight end. Month after photodynamic therapy, the second stage of treatment is performed, in which the enriched platelets enrich the patient's own plasma with a dose of 3.5 ml into mesothelioma by mesotherapy. Conduct from 3 to 5 procedures with an interval between procedures in 2 weeks. At the same time, intravenous laser irradiation of the blood (VLOK) is performed. To do this, use a device with a wavelength of 0.63 microns. Procedures VLOK conducted daily or every other day.EFFECT: method provides effective and gentle treatment while reducing the time of rehabilitation due to resorption of abnormal cells, rapid regeneration of damaged tissues, elimination of human papillomavirus and herpes virus as a result of synergistic immunomodulatory and antiviral effects of complex effects.1 cl, 1 tbl
OBJECTIVE: To analyze the effects and tolerability of physiotherapeutic methods with optical radiation (phototherapy) in acute respiratory diseases (ARD) on the basis of the modern scientific literature data and the results of doctors and patients survey.
MATERIAL AND METHODS: An analysis of regulatory sources and modern scientific literature on the subject of research, survey of 200 patients with ARD and 100 primary care physicians of the Central Federal District on their sociomedical status and awareness of phototherapeutic treatment methods were conducted.
RESULTS: Phototherapy in ARD have demonstrated chromogenic, immunostimulating, photosensitizing, vitamin-forming, trophostimulating, anti-inflammatory, analgesic, desensitizing, bactericidal and mycocidal, metabolic, coagulo-correcting therapeutic effects. Patients and doctors have been insufficiently aware of phototherapy methods and used them in practice relatively rare. A significant proportion of patients had ARD risk factors, namely teamwork, tobacco smoking and chronic diseases.
CONCLUSION: 1. The therapeutic effects of all types of phototherapy in acute respiratory infections are interrelated with their etiopathogenesis. 2. Patients and doctors are insufficiently informed and relatively rarely use phototherapy methods. 3. A significant proportion of patients have risk factors for acute respiratory infections: teamwork (88%), tobacco smoking (68%) and chronic diseases (52%).
Ulcerative colitis (UC) is an idiopathic chronic intestinal inflammation. An increasing body of evidence shows that macrophages play an important role in the pathogenesis of UC. Interferon regulatory factor 4 (IRF4) is crucial for the development of autoimmune diseases via regulating immune cells. This research was designed to explore the function of IRF4 in UC and its association with macrophage polarization. The in vitro model of UC was established by stimulating colonic epithelial cells with tumor necrosis factor α (TNF-α). A mouse model of UC was constructed by injecting C57BL/6 mice with dextran sulfate sodium salt. Flow cytometry was used to assess percentage of CD11b+ CD86+ and CD11b+ CD206+ cells in bone marrow macrophages. Occult blood tests were used to detect hematochezia. Hematoxylin and eosin staining assay was used to assess colon pathological changes. Enzyme-linked immunosorbent assay (ELISA) was used to detect concentrations of inflammatory cytokines. The interaction of IRF4 and B-cell lymphoma 6 (Bcl6) was confirmed using GST pull-down and coimmunoprecipitation assays. Our findings revealed that IRF4 promoted cell apoptosis and stimulated M1 macrophage polarization in vitro. Furthermore, IRF4 aggravated symptoms of the mouse model of UC and aggravated M1 macrophage polarization in vivo. IRF4 negatively regulated Bcl6 expression. Downregulation of Bcl6 promoted apoptosis and M1 macrophage polarization in the presence of IRF4 in vitro and in vivo. Moreover, Bcl6 positively mediated the Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) signaling pathway. In conclusion, IRF4 aggravated UC progression through promoting M1 macrophage polarization via Bcl6/JAK2/STAT3 pathway. These findings suggested that IRF4 might be a good target to competitively inhibit or to treat with UC.
The solution falls with the branch of synthesis of pharmaceuticals. Its principle consists in method of preparation of 2-(4-(2-propylthio)phenyl)propionic acid. This substance is characteristic by its antiphlogistic and analgesic effects and can be used practically in pharmacotherapy. In comparison with generally known ibuprofen (registered trademark) it has comparable antiphlogistic effect and gastrotoxicity. Its advantages consist in higher analgesic effect and lower acute toxicity in mice administered orally. The preparation method of the substance I according to the solution consists in reaction of 2-(4-mercaptophenyl)propionic acid with 2-brompropane in dimethylformamide in presence of potassium carbonate at a temperature of 50 to 80 degrees C and in subsequent hydrolysis of non-characterised intermediary product by boiling solution of sodium hydroxide in aqueous ethanol.
Intravenous deferoxamine: bolus of 10mg/Kg (initiated during tPA infusion) and perfusion of 20/40/60 mg/Kg/day during 72h. Three different doses (3 steps), 15 patient in the active arm for each dose.
An acyloxyacyl hydrolase from the human promyelocyte cell line HL-60 has been found to specifically hydrolyze fatty acids from their ester linkages to hydroxy groups of 3-hydroxyfatty acids, the latter being being bound in turn to lipopolysaccharide glycosaminyl residues. The hydrolyzed fatty acids may include dodecanoic acid, tetradecanoic acid and hexadecanoic acid. This enzyme showed a molecular weight by gel exclusion chromatography between about 50,000 Daltons and about 70,000 Daltons, and a molecular weight by polyacrylamide gel electrophoresis with sodium dodecylsulphate, using reduced molecular weight standards, of approximately 54,000 to 60,000 Daltons. Altered bacterial lipopolysaccharide substantially without fatty acids bound in ester linkage to hydroxy groups of 3-hydroxyfatty acids covalently linked to a glucosaminyl moiety of lipopolysaccharide lipid A are produced. Since the structure of the lipid A moiety is highly conserved, acyloxyacyl hydrolase may act on lipopolysaccharide of many different pathogenic bacteria (for example Salmonella, Escherichia, Hemophilus, and Neisseria). Such altered bacterial lipopolysaccharide, having toxicity reduced more than immunostimulatory activity, may be therapeutically useful: (1) as vaccines to prevent Gram-negative bacterial diseases by inducing antibodies to lipopolysaccharide O-polysaccharide or R-core antigens, (2) as antidotes to treat or prevent Gram-negative bacterial sepsis ("septic shock"), or (3) as adjuvants to enhance formation of antibodies to other antigens. the acyloxyacyl hydrolase itself may be prophylactically or therapeutically useful to detoxify endogenous lipopolysaccharide in patients with Gram-negative bacterial diseases. The enzyme may also be used to remove toxic lipopolysaccharide from therapeutic injectants.
Liposomal and/or nano-liposomal encapsulated HSP90a, HPf polypeptide (115 aa) and novel polypeptides HPf ?C1 (101 aa) and HPf?C2 (87 aa), as well as methods for manufacturing/preparing and using the compositions, are disclosed. Chimeric fusion proteins that include an HSP90a, HPf-polypeptide, HPf ?C1 or HPf?C2 polypeptide are presented. Transformed cell lines and expression vectors capable of expressing the chimeric fusion proteins, are provided. Methods for producing large amounts of recombinant HSP90a, HPf polypeptide, HPf ?C1 or HPf?C2 polypeptide, using expression vectors and transformed cell lines, are described. Topical and other delivery form preparations and methods for using the preparations, including methods for improving skin conditions (atopic dermatitis, wrinkles, skin elasticity, dark spots (over pigmentation), overall skin rejuvenation, skin ageing) for therapeutic and cosmeceutical uses are presented. Liposomal preparations and methods for using them for enhancing wound healing and methods for suppressing subcutaneous fat cell differentiation and reducing subcutaneous fat formation are disclosed.
Beverages comprise a cariostatic agent consisting of a water-soluble, bland-tasting phosphate ester of a polyhydric alcohol a cyclitol (an alicyclic polyhydric alcohol), a sugar or an oligo- or poly-saccharide, or a salt of such an ester, including mixtures of such esters or salts, and a carrier suitable for oral intake. Prepared ester salts are those of calcium, sodium and magnesium e.g. calcium sucrose phosphate, calcium lactose phosphate and calcium glucose phosphate.  The beverage may contain liquid sugar and calcium sucrose phosphate.  Specification 572,352 is referred to.ALSO:Pharmaceutical preparations and dentifrices comprise a cariostatic agent consisting of a water soluble, bland-tasting phosphate ester of a polyhydric alcohol, a cyclitol (alicyclic polyhydroxy alcohol), a sugar or an oligo- or poly-saccharide, or a salt of such an ester, including mixtures of such esters or salts, and a carrier thereof suitable for oral intake.  Preferred ester salts are those of calcium, sodium and magnesium e.g. calcium sucrose phosphate, calcium lactose phosphate and calcium glucose phosphate. The dentifrice may be liquid paste or powder and apart from conventional ingredients may contain fluorides in addition to the phosphate ester.  The pharmaceutical preparation may be in the form of a tablet or lozenge.  Sugar may be coated with the cariostatic agent.  Specification 572,352 is referred to.
A filling device for filling a removable medication cartridge for the smart medication dispenser is provided. The filling device includes a stationary fill plate with a plurality of openings. The openings are shaped to allow the passage of medications through the fill plate. The cartridge is removably positioned vertically below the fill plate and with the chambers of the cartridge being aligned with the openings of the fill plate. A gate is positioned vertically below the fill plate and above the cartridge. When in a closed position, the gate covers the openings from beneath the fill plate, and movement of the gate to an open position causes at least one medication to fall through at least one of the openings from above the stationary fill plate into at least one of the chambers in the cartridge prior to removal of the medication cartridge with the medications received within the chambers.
Currently, all eligible goalball players compete together irrespective of their level of vision impairment, yet it remains unclear whether those with more impairment are disadvantaged during competition. Following the International Paralympic Committee's requirement for evidence-based, sport-specific classification, this study assessed whether individual goalball performance relates to the level of visual impairment. Using results from the 2016 and 2020 Paralympic Games, players' sport classes and in-competition key performance statistics (minutes played, throws per minute, goals per minute, penalties conceded per minute, blocks per minute, and goals per throw) were extracted. Players' visual acuity and visual field results were obtained through the IBSA Sport Administration System. Results showed no statistically significant differences in performance between classes. Further, there were no significant relationships between vision and performance for all six variables for female players. A small but significant positive correlation was found between visual acuity and the number of penalties conceded for male players. Collectively, the results suggest that currently eligible players compete fairly against one another during competitive goalball matches. Results provide support for the existing system of classification whereby all eligible athletes compete against each other irrespective of their level of impairment.
The invention provides a traditional Chinese medicine composition for adjunctive Aids treatment and applications thereof. Active ingredients of the composition comprise wild buckwheat and one to three of astragalus membranaceus, root-bark of Chinese wolfberry and cape jasmine. The composition has the functions of heat clearing, toxicity removing, pus eliminating and stasis removing. In clinic, the composition is used for treating Aids-epidemic heat syndrome, the pathogenic heat lung congestion symptom and the spleen and vagina heat invasion symptom. According to clinical results, when the composition is used in cooperation with efficient anti-retroviral drugs for treating, the effects of improving clinical adverse symptoms of patients and enhancing immune functions are realized. According to animal experimental results, the composition has a positive adjusting effect on the nonspecific immune function and the cellular immune function of mice with low immune functions.
There are several different medications commonly being used to facilitate the administration of radiologic procedures on children. Procedures such as Magnetic Resonance Imaging (MRIs) require that the patient remain still for the duration of the test. Propofol has become the drug of choice for many sedation services due to its rapid onset of action, rapid recovery time, ability to achieve sedation reliably and favorable safety profile. Dexmedetomidine, a selective alpha-2- adrenergic agonist, has also gained popularity with sedation services. Its main advantage over propofol is that it has minimal respiratory complications when compared to propofol. The sedative effect from dexmedetomidine preserves a natural sleep pattern and induces cooperative sedation in which patients are easily arousable. In pediatric studies, the most frequent adverse effect have been related to its potential to cause hypotension and bradycardia, which resolve with dose reduction. Additionally, dexmedetomidine does not seem to have as much impairment of cognitive function and has an opioid sparing effect. Dexmedetomidine, however, has a longer onset of action and longer recovery time compared to propofol, which has limited its use with many sedation services.
C3 and C4 dosing groups: The drug is given on the day of the C3 and C4 chemotherapy cycles and is administered for 10 days. The drug is placed deep into the vagina after washing the vulva, once a night, 1 capsules each time.
Live vaccines are provided and methods for preparing the live vaccines for protection of a host from a pathogenic microorganism. The vaccines are prepared by introducing at least one modification in a gene involved in at least one, normally at least two, biosynthetic pathways involving the production of products which are unlikely to be found in the disease susceptible host. The modification results in a gene change which cannot be repaired by a single step, e.g. polynucleotide deletions and inversions. Where the aro gene suffers such a change, the resultant auxotrophic mutants require aromatic amino acids, p-aminobenzoic acid and 2,3-dihydroxybenzoic acid or a highly concentrated source of absorbable iron. The auxotrophic mutations have substantially reduced or nonexistent virulence while retaining the desired immunogenicity to initiate the immunogenic response. Various techniques can be employed for providing the desired change.
<P>PROBLEM TO BE SOLVED: To provide artificially fused proteins (AFP) designed so as to elicit an anti-HIV immune response, as well as a nucleic acid molecule and expression vector encoding the proteins.  <P>SOLUTION: The AFPs may comprise various HIV proteins, e.g. domains originated from Gag, Pol, Vif and Env proteins which are partial sequences. HIVCON has HIV domains derived from several HIV-clade consensus sequences, and may contain additional domains which may be useful for monitoring the expression level or immune response of experimental animals. In order to induce cell-mediated immune responses preferably with a DNA prime-MVA boost strategy, compositions and methods for inducing an anti-HIV immune responses in a subject can be included.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Orencia Group is for RA patients who have not received any other biologic treatment, including abatacept previously, and whose doctor has determined that it is appropriate to treat their RA with Abatacept. If you are in Group 1, you will receive the study drug, Abatacept, given in an intravenous (IV - injected into a vein) as well as subcutaneous form. Abatacept, given in an intravenous injection is approved by the FDA for the treatment of RA.
NEW MATERIAL:A compound expressed by the formula. USE:A circulatory organ disease treating agent, hair tonic and cosmetic. The above-mentioned compound has wide action, e.g. circulation improving effect such as vasodilation or vasodepressor activity, action for keeping and improving the skin from chapping as well as trichogenous promoting and alopecia preventing effects. PREPARATION:3-(3,4-Dihydroxyphenyl)2-methyl-L-alanine is reacted with hydrate (alpha-methyldopa) and benzoyl chloride to provide the compound expressed by the formula. The compound expressed by the formula is single or mixed with a common medicine additive and formulated according to ordinary method to provide the remedy for circulatory organ disease. The remedy can be orally or parenterally administered and the dose is 0.5-500mg/1kg wt. daily in oral administration.
FIELD: neurology and neurosurgery. SUBSTANCE: spatial position of patient is preliminarily changed from orthostasis to antiorthostasis. If one observes pathological symptomatic regress in patient's position of head below level of legs by 30-45 deg., intratympanical streptomycin is administered on the side opposite to maximally expressed symptomatic. Injection is performed 2 times a week during 1 to 2 weeks in doses 0.5 to 1 g. If necessary, treatment course is repeated but no sooner than 6 months later. EFFECT: achieved more durable and stable remission or completely regressed symptomatic. 4 ex
The present invention discloses a Chinese medicine composition for treating cough after a common cold and cough variant asthma. The composition is composed of an effective component and/or a carrier which is acceptable on pharmacy, wherein the effective component is mainly prepared by Chinese ephedra, perilla leaf, perillae, earthworm, etc. The Chinese medicine composition is prepared into an optional preparation on pharmacy. The Chinese medicine composition has the obvious functions for relieving cough, resisting phlogosis, relieving asthma, resolving phlegm, supplying immunity, etc. The Chinese medicine composition can enhance threshold of reaction and Dmin of an air passage for acetyl-beta-methylcholine chloride, and can obviously reduce sGrs and peripheral blood EOS, ECP and IL-5. The reduction range is obviously greater than that caused by combination of a fluorine preparation and becotide spray in a control group. Therefore, the Chinese medicine composition can relieve symptoms of patients who cough after a common cold and have cough variant asthma, can greatly improve the patient's atopia habitus, and can reduce the high reaction and the high sensitivity of the air passage. The present invention simultaneously relates to a preparation method of the Chinese medicine composition.
Systems, methods, and devices for forming an array of emulsions. An exemplary device comprises a frame and at least one or a plurality of separate microfluidic modules mounted to the frame and each configured to form an array of emulsions. In some embodiments, each module may be mounted by snap-fit attachment. The device also may include the same sealing member bonded to a top side of each module and hermetically sealing each of the modules. Another exemplary microfluidic device for forming an array of emulsions comprises a stack of layers bonded together. The stack may comprise a port layer forming a plurality of ports. Each port may have a top rim formed by a protrusion that encircles the central axis of the port. The rims may be coplanar with one another to facilitate bonding of a sealing member to each rim.
The invention relates to a method and an apparatus for selecting a medical accessory for treatment of a patient. The method comprises at least one of the following method steps. A first method step of receiving a patient identifier identifying the patient to be treated. A second method step of determining a treatment identifier of the treatment to be performed which identifies the treatment to be performed on the patient. A third method step of comparing an accessory database containing data sets on at least two medical accessories for one or more patient treatments to an actual inventory of stocked medical accessories. A fourth method step of selecting a suitable medical accessory for a treatment to be performed on the patient by means of the accessory database and on the basis of at least the patient identifier, the treatment identifier and the actual inventory. A fifth method step of segregating the selected medical accessory.
Safety and effectiveness in pediatric patients have not been established. Large and repeated doses of estrogen over an extended period of time have been shown to accelerate epiphyseal closure, resulting in short adult stature if treatment is initiated before the completion of physiologic puberty in normally developing children. In patients in whom bone growth is not complete, periodic monitoring of bone maturation and effects on epiphyseal centers is recommended.

  


Estrogen treatment of prepubertal children also induces premature breast development and vaginal cornification, and may potentially induce vaginal bleeding in girls. In boys, estrogen treatment may modify the normal pubertal process. All other physiological and adverse reactions shown to be associated with estrogen treatment of adults could potentially occur in the pediatric population, including thromboembolic disorders and growth stimulation of certain tumors. Therefore, estrogens should only be administered to pediatric patients when clearly indicated and the lowest effective dose should always be utilized.
Safety and effectiveness of diflunisal in pediatric patients below the age of 12 have not been established. Use of diflunisal tablets in pediatric patients below the age of 12 is not recommended.

The adverse effects observed following diflunisal administration to neonatal animals appear to be species, age, and dose-dependent. At dose levels approximately 3 times the usual human therapeutic dose, both aspirin (200 to 400 mg/kg/day) and diflunisal (80 mg/kg/day) resulted in death, leukocytosis, weight loss, and bilateral cataracts in neonatal (4 to 5-day-old) beagle puppies after 2 to 10 doses. Administration of an 80 mg/kg/day dose of diflunisal to 25-day-old puppies resulted in lower mortality, and did not produce cataracts. In newborn rats, a 400 mg/kg/day dose of aspirin resulted in increased mortality and some cataracts, whereas the effects of diflunisal administration at doses up to 140 mg/kg/day were limited to a decrease in average body weight gain.
<P>PROBLEM TO BE SOLVED: To economically produce arachidonic acid and to provide a food formulated with the same.  <P>SOLUTION: Mortierella sect. schmuckeri microorganisms are cultured in fermentation medium, preferably containing a component of a complex nitrogen source. The arachidonic acid is important as a precursor of eicosanoid which is a nutrient for infant, and a food product which includes Mortierella sect. schmuckeri microorganisms or lipid isolated from such microorganisms to enhance the arachidonic acid content of the food product for infant is produced.  <P>COPYRIGHT: (C)2008,JPO&INPIT